— Know what they know.
Not Investment Advice
Also trades as: GSK (NYSE) · $vol 208M · GSK.L (LSE) · $vol 186M · GS7.DE (XETRA) · $vol 2M

GLAXF OTC

GSK plc
1W: +5.6% 1M: +7.1% 3M: -1.7% YTD: +11.5% 1Y: +21.0% 3Y: +61.5% 5Y: +30.3%
$26.12
+1.22 (+4.90%)
After Hours: $25.62 (-0.50, -1.93%)
OTC · Healthcare · Drug Manufacturers - General · Tech Score Buy · Power 60 · $104.7B mcap · 3.88B float · 0.0000% daily turnover · Short 54% of daily vol
Credit Risk of going bust: lower than 77% of companies Debt: 19.1% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.43 (down 98%), GSK plc would be worth roughly what it owes.
Total debt $24.20B against a stock market value of $102.38B.
Distance to default 9.00 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $14.94B (short-term plus half of long-term), stock volatility 26.2%; Altman Z'' 1.49. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Smart Money Score
Watch 0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$104.7B
52W Range20.97-31.48
Volume4
Avg Volume1,198
Beta0.30
Dividend$0.91
Analyst Ratings
No analyst coverage
Company Info
CEOLuke Victor Miels
Employees66,841
SectorHealthcare
IndustryDrug Manufacturers - General
IPO Date2010-01-05
Websitegsk.com
79 New Oxford Street
London, GL WC1A 1DG
GB
44 20 8047 5000
About GSK plc

GSK plc, a global healthcare and pharmaceutical leader with roots tracing back to 1715, is headquartered in Brentford, United Kingdom. Operating extensively across the UK, United States, and other international markets, its activities span the entire lifecycle of healthcare products, encompassing research, development, manufacturing, and commercialization. Its broad portfolio includes pharmaceuticals, vaccines, over-the-counter medications, and a range of health-focused consumer products. The company operates through four primary divisions: Pharmaceuticals, Pharmaceutical Research & Development, Vaccines, and Consumer Healthcare. Within its pharmaceutical arm, GSK provides therapeutic solutions for a broad spectrum of conditions. These include ailments in respiratory health, HIV, immuno-inflammation, oncology, viral infections, central nervous system disorders, cardiovascular and urogenital issues, metabolic diseases, bacterial infections, and dermatology. The consumer healthcare division delivers products across wellness, oral health, nutrition, and skin health categories. These are available in numerous formats, including nasal sprays, tablets, syrups, lozenges, gum and transdermal patches, caplets, infant syrup drops, liquid suspensions, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams, non-medicated patches, lip balms, gummies, and soft chews. GSK also maintains collaborative agreements with various organizations such as 23andMe, Lyell Immunopharma, Inc., Novartis, Sanofi SA, Surface Oncology, Progentec Diagnostics, Inc., Alector, Inc., and CureVac AG. Furthermore, strategic partnerships are in place with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The firm, known as GlaxoSmithKline plc until its name change to GSK plc in May 2022, embodies centuries of innovation in healthcare.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms